Literature DB >> 11535008

Levodopa responsive Parkinsonism in adults with Angelman Syndrome.

M Harbord1.   

Abstract

Two intellectually disabled adults with Angelman Syndrome are reported who developed intermittent episodes of a severe resting tremor, cogwheel rigidity and bradykinesia in their late teens. The Parkinsonism was not due to medications and there was a dramatic improvement with levodopa therapy. The association between Angelman Syndrome and Parkinsonism has not previously been described. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11535008     DOI： 10.1054/jocn.2000.0753

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN： 0967-5868            Impact factor:   1.961


  17 in total

Review 1.  E3 ubiquitin ligases in protein quality control mechanism.

Authors:  Deepak Chhangani; Ajay Prakash Joshi; Amit Mishra
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

Review 2.  Angelman Syndrome.

Authors:  Seth S Margolis; Gabrielle L Sell; Mark A Zbinden; Lynne M Bird
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

3.  Integration of CpG-free DNA induces de novo methylation of CpG islands in pluripotent stem cells.

Authors:  Yuta Takahashi; Jun Wu; Keiichiro Suzuki; Paloma Martinez-Redondo; Mo Li; Hsin-Kai Liao; Min-Zu Wu; Reyna Hernández-Benítez; Tomoaki Hishida; Maxim Nikolaievich Shokhirev; Concepcion Rodriguez Esteban; Ignacio Sancho-Martinez; Juan Carlos Izpisua Belmonte
Journal:  Science       Date:  2017-05-05       Impact factor: 47.728

4.  A randomized controlled trial of levodopa in patients with Angelman syndrome.

Authors:  Wen-Hann Tan; Lynne M Bird; Anjali Sadhwani; Rene L Barbieri-Welge; Steven A Skinner; Lucia T Horowitz; Carlos A Bacino; Lisa M Noll; Cary Fu; Rachel J Hundley; Logan K Wink; Craig A Erickson; Gregory N Barnes; Anne Slavotinek; Rita Jeremy; Alexander Rotenberg; Sanjeev V Kothare; Heather E Olson; Annapurna Poduri; Mark P Nespeca; Hillary C Chu; Jennifer M Willen; Kevin F Haas; Edwin J Weeber; Paul A Rufo
Journal:  Am J Med Genet A       Date:  2017-09-25       Impact factor: 2.802

5.  Pathway-specific dopaminergic deficits in a mouse model of Angelman syndrome.

Authors:  Thorfinn T Riday; Elyse C Dankoski; Michael C Krouse; Eric W Fish; Paul L Walsh; Ji Eun Han; Clyde W Hodge; R Mark Wightman; Benjamin D Philpot; C J Malanga
Journal:  J Clin Invest       Date:  2012-11-12       Impact factor: 14.808

6.  Motor Deficits Coupled to Cerebellar and Striatal Alterations in Ube3am-/p+ Mice Modelling Angelman Syndrome Are Attenuated by Adenosine A2A Receptor Blockade.

Authors:  Ana Moreira-de-Sá; Francisco Q Gonçalves; João P Lopes; Henrique B Silva; Ângelo R Tomé; Rodrigo A Cunha; Paula M Canas
Journal:  Mol Neurobiol       Date:  2021-01-19       Impact factor: 5.590

Review 7.  Drosophila modeling of heritable neurodevelopmental disorders.

Authors:  Cheryl L Gatto; Kendal Broadie
Journal:  Curr Opin Neurobiol       Date:  2011-05-17       Impact factor: 6.627

Review 8.  Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes.

Authors:  Angela M Mabb; Matthew C Judson; Mark J Zylka; Benjamin D Philpot
Journal:  Trends Neurosci       Date:  2011-05-17       Impact factor: 13.837

9.  E6AP in the brain: one protein, dual function, multiple diseases.

Authors:  Jimmy El Hokayem; Zafar Nawaz
Journal:  Mol Neurobiol       Date:  2013-10-05       Impact factor: 5.590

10.  Ca(2+)/calmodulin-dependent protein kinase IIα (αCaMKII) controls the activity of the dopamine transporter: implications for Angelman syndrome.

Authors:  Thomas Steinkellner; Jae-Won Yang; Therese R Montgomery; Wei-Qiang Chen; Marie-Therese Winkler; Sonja Sucic; Gert Lubec; Michael Freissmuth; Ype Elgersma; Harald H Sitte; Oliver Kudlacek
Journal:  J Biol Chem       Date:  2012-07-09       Impact factor: 5.486
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.